Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Hydronidone With Antiviral Agents in Healthy Subjects
NCT07295873Phase 1Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hydronidone in Liver Fibrosis (LF) (4 arms), sponsored by Gyre Pharmaceuticals. Primary endpoints: Steady-state peak concentration at 23 days and Area under the plasma concentration-time curve from time zero to 24 hours at steady state. Started Mar 2026; status: completed.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT07295873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295873.